Vir Biotechnology, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Vir Biotechnology, Inc. now
Current reporting with the operating signal separated from the noise.
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Investors are testing whether Vir Biotechnology, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
Investors are testing whether Vir Biotechnology, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Vir Biotechnology, Inc.: Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic ...
The story matters when it changes Vir Biotechnology, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest VIR filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Vir Biotechnology, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →